Study title: I0016g(A),CH 9903,137.41 - An open phase III follow-up (5 years) trial of recombinant human interferon gamma-1b in patients with chronic granulomatous disease (CGD) to evaluate safety and efficacy of long-term interferon gamma-1b treatment - 5-year-follow-up safety report.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases [C20] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: INTERFERON GAMMA (1B) | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: I0681s | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |